Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06833 Sinco Pharmaceuticals
0.285
-0.015-5.00%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Cash flow from operating activities
Earning before tax
23.12% 167.39M 203.93% 91.68M 216.51% 135.96M 38.44% 30.17M
Profit adjustment
Interest (income) - adjustment
60% -518K -25.51% -246K -316.4% -1.3M -136.14% -196K
Impairment and provisions:
-70.94% 856K 97.76% -38K 113.79% 2.95M -130.39% -1.69M
-Impairmen of inventory (reversal)
-- -- -- -- 2964.15% 3.25M -- 563K
-Impairment of trade receivables (reversal)
391.43% 1.02M 75.04% -454K -126.4% -350K -132.34% -1.82M
-Other impairments and provisions
-441.67% -164K 194.98% 416K 188.89% 48K -776% -438K
Revaluation surplus:
-- 0 -- 0 -- 0 -- 0
Asset sale loss (gain):
-- 0 -- 0 -- 0 -- 0
Depreciation and amortization:
-28.88% 6.7M -37.13% 3.37M -9.44% 9.42M 2.31% 5.36M
-Depreciation
-28.94% 6.68M -37.4% 3.27M -9.07% 9.4M 0.87% 5.23M
-Amortization of intangible assets
-4.35% 22K 0% 12K -66.18% 23K -78.57% 12K
-Other depreciation and amortization
-- -- -29.17% 85K -- -- -- 120K
Financial expense
231.52% 29.16M 1120.16% 14.83M -56.07% 8.8M -88.1% 1.22M
Unrealized exchange loss (gain)
222.64% 3.55M 10143.75% 1.64M 1846.03% 1.1M 133.33% 16K
Special items
91% -825K 88.79% -518K -48331.58% -9.16M -- -4.62M
Operating profit before the change of operating capital
39.63% 206.31M 266.06% 110.72M 98.48% 147.76M -29.14% 30.25M
Change of operating capital
Inventory (increase) decrease
1247.19% 181.29M 1594.68% 142.52M 130.2% 13.46M -104.75% -9.54M
Accounts receivable (increase)decrease
166.48% 364.06M 537.11% 280.99M -9246.77% -547.63M -64.71% -64.28M
Accounts payable increase (decrease)
-172.09% -371.08M -281.67% -406.43M 1438.31% 514.73M -76.32% -106.49M
prepayments (increase)decrease
317.71% 627K -- -- -101.1% -288K -- --
Cash  from business operations
142.39% 346.89M 215.56% 95.67M 31831.71% 143.11M -167.33% -82.79M
Other taxs
-486.78% -41.69M -132.15% -14.24M 24.48% -7.11M -55.96% -6.13M
Interest received - operating
-60% 518K 25.51% 246K 316.4% 1.3M 136.14% 196K
Special items of business
-327.62% -34.32M -147.76% -32.13M 117.92% 15.08M 262.53% 67.27M
Net cash from operations
122.66% 305.71M 192.05% 81.67M 1538% 137.3M -174.49% -88.73M
Cash flow from investment activities
Purchase of fixed assets
-6223.12% -23.52M -23822.22% -2.15M 32.97% -372K 91.09% -9K
Recovery of cash from investments
-- -- -- -- -- 1.99M -- --
Other items in the investment business
101.64% 795K -78.01% 518K -2335.18% -48.46M 2839.53% 2.36M
Net cash from investment operations
51.48% -22.73M -169.66% -1.64M -1740.55% -46.84M 1355.08% 2.35M
Net cash before financing
212.84% 282.99M 192.66% 80.04M 848.02% 90.46M -172.64% -86.38M
Cash flow from financing activities
New borrowing
74.52% 210M 272.63% 170M 153.41% 120.33M -- 45.62M
Refund
65.56% -77.94M 65.3% -48.57M -4426.24% -226.31M -2700% -140M
Issuing shares
-- 75.37M -- -- -- -- -- --
Interest paid - financing
-227.34% -22.47M 58.41% -9.82M 36.89% -6.87M -130.63% -23.62M
Pledged bank deposit (increase) decrease
-- -55.02M 52.74% -17.62M -- -- -- -37.27M
Other items of the financing business
-298.15% -227.06M -147.71% -49.17M -145.68% -57.03M 167.54% 103.04M
Net cash from financing operations
42.84% -97.11M 185.83% 44.83M -208.59% -169.88M 68.88% -52.22M
Effect of rate
-128.08% -3.59M -984% -1.63M -2598.41% -1.57M -412.5% -150K
Net Cash
334.05% 185.88M 190.09% 124.86M -155.02% -79.42M -183.51% -138.6M
Begining period cash
-36.04% 143.77M -36.04% 143.77M 179.75% 224.76M 179.75% 224.76M
Cash at the end
126.8% 326.05M 210.45% 267M -36.04% 143.77M 173% 86M
Cash balance analysis
Cash and bank balance
-- -- 173.2% 234.97M -- -- -- 86M
Cash and cash equivalent balance
-- 0 173.2% 234.97M -- 0 -- 86M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO: Xiangbin Huang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...